ArticleMetabolomics : Official journal of the Metabolomic Society2025
Metabolomic and lipidomic profiling of plasma in kidney stone patients: identification of potential biomarkers and therapeutic targets.
Article in Metabolomics : Official journal of the Metabolomic Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Evidence-based recommendations for preventing recurrence in patients with urinary tract stones.International urology and nephrology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundKidney stone are among the most common urologic diseases characterized with metabolic disorder. Biomarker for kidney stone detection and the metabolic variables in kidney stone development have attracted increasing attention.
methodsTo explore the metabolomic and lipidomic characteristics of plasma in patients with kidney stones, we collected plasma samples from 200 participants, including 100 kidney stone patients and 100 healthy controls. We designated 59 patients with clearly defined stone compositions alongside matched healthy individuals as the training set (n = 118), while the remaining 41 patients with unclear stone compositions were paired with healthy individuals and served as the test set (n = 82).
resultsA total of 333 and 270 metabolites were significantly altered in kidney stone patients under positive and negative ion modes, respectively, compared to healthy controls. KEGG analysis indicated that pathways such as Arginine and proline metabolism, Citrate cycle (TCA cycle), Alanine, aspartate and glutamate metabolism and phenylalanine metabolism, were closely associated with kidney stone formation. Moreover, a total of 416 lipids were significantly changed in the Kidney stone group and the control group. Using Lasso model, a panel of integrated 4 metabolites and 4 lipids showed effective discrimination between Kidney stone group and the control group. Among these metabolites, Isorhamnetin has the potential to effectively reduced oxalate-induecd acute kidney injury, hence lowering the likelihood of stone formation.
conclusionsThese findings offer novel insights into the metabolic and lipidomic alterations associated with kidney stones, providing potential biomarkers for early diagnosis and therapeutic targets for intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.